|
| Press Releases |
|
 |
|
| Wednesday, July 1, 2020 |
|
|
Hua Medicine Announces Positive 24-Week Topline Results of Phase III Metformin Combination Trial of Dorzagliatin |
| Hua Medicine today announced the positive 24-week top-line results from HMM0302, a Phase III registration trial in China of its global first-in-class glucokinase activator dorzagliatin add-on to metformin, a first line oral antidiabetic therapy in Type 2 diabetes. more info >> |
|
| Thursday, June 18, 2020 |
|
|
Hua Medicine Successfully Completes SEED (HMM0301), Dorzagliatin Phase III Monotherapy Trial |
| Hua Medicine (the "Company", Stock Code: 2552.HK), a leading innovative drug development company focused on developing novel therapies for the treatment of diabetes, today announced topline results from SEED (also known as HMM0301) more info >> |
|
| Monday, April 27, 2020 |
|
|
Hua Medicine Announces Positive Results in the Combination Study of Dorzagliatin with Empagliflozin (a SGLT-2 inhibitor) |
| Hua Medicine (the "Company", Stock Code: 2552. HK) today announces the positive results of the clinical study HMM0112. more info >> |
|
| Monday, March 16, 2020 |
|
|
Hua Medicine Announces 2019 Annual Results |
| Hua Medicine (the "Company", Stock Code on The Stock Exchange of Hong Kong Limited: 2552.HK), a global innovative drug research and development company focused on novel therapies for the treatment of diabetes, today announces the audited consolidated results of the Company and its subsidiaries for the year ended December 31, 2019. more info >> |
|
| Friday, February 14, 2020 |
|
|
Hua Medicine appoints Dr. Fuxing Tang, a former U.S. FDA Officer, as Chief Technology Officer |
| Hua Medicine, a leading clinical stage biotechnology company based in Shanghai, is pleased to announce that Dr. Fuxing Tang has joined Hua Medicine as Chief Technology Officer, VP of Formulation R&D and Product Development. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Transgene and NEC Present Durable Disease-Free Survival and Sustained T Cell Responses at 24 months with Individualized Cancer Vaccine TG4050
Jun 2, 2025 17:56 JST
|
|
|
Eisai to Launch "Pariet S," the First Proton Pump Inhibitor RX-to-OTC in Japan
Jun 2, 2025 17:46 JST
|
|
|
New HKTDC Chairman Professor Frederick Ma Si-Hang meets with management team
Jun 2, 2025 16:35 HKT/SGT
|
|
|
Mitsubishi Corporation to Invest and Enter into a Business Partnership with DEScycle Ltd., a UK Company Developing Innovative Metal Recycling Technology
Jun 2, 2025 14:35 JST
|
|
|
MyJCB App Wins Gold at A' Design Award & Competition 
Jun 2, 2025 12:00 JST
|
|
|
Fujitsu Technology Park's redevelopment project launch
Jun 2, 2025 11:23 JST
|
|
|
Wasion Holdings Subsidiaries Secure Over HK$253 Million in Contracts from State Grid's 2025 First Metering Equipment Tender
Jun 2, 2025 09:43 HKT/SGT
|
|
|
TransNusa Increases Scheduled Flight Frequency to Twice Daily
Jun 2, 2025 08:30 HKT/SGT
|
|
|
Shiv Khera's New Book "Live While You're Alive" Launched in Singapore
Jun 2, 2025 03:30 HKT/SGT
|
|
|
Hola Prime Launches Performance Coaching Initiative to Tackle the #1 Barrier to Trader Success: The Mind
May 30, 2025 19:00 HKT/SGT
|
|
|
Mitsubishi Corporation Establishes New Corporate Venture Capital Company
May 30, 2025 18:36 JST
|
|
|
The PropertyGuru Asia Property Awards (Middle East) return for 2025 edition with inaugural Dubai launch
May 30, 2025 14:00 HKT/SGT
|
|
|
Honda to Co-develop Refueling Port Connecting System for On-orbit Satellite Refueling with Astroscale
May 30, 2025 11:54 JST
|
|
|
IFS and NEC Strengthen their Strategic Partnership to Create New Value
May 30, 2025 10:11 JST
|
|
|
Genetec maintains profitability in Q3FY2025 on higher revenue
May 29, 2025 20:00 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
